Bone Biologics Statistics
Share Statistics
Bone Biologics has 3.27M
shares outstanding. The number of shares has increased by 197.24%
in one year.
| Shares Outstanding | 3.27M |
| Shares Change (YoY) | 197.24% |
| Shares Change (QoQ) | 32.78% |
| Owned by Institutions (%) | 3.44% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,158 |
| FTD / Avg. Volume | 1.96% |
Short Selling Information
The latest short interest is 72.41K, so 2.21% of the outstanding
shares have been sold short.
| Short Interest | 72.41K |
| Short % of Shares Out | 2.21% |
| Short % of Float | 2.22% |
| Short Ratio (days to cover) | 4.35 |
Valuation Ratios
The PE ratio is -0.35 and the forward
PE ratio is -0.38.
Bone Biologics's PEG ratio is
0.
| PE Ratio | -0.35 |
| Forward PE | -0.38 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.41 |
| P/FCF Ratio | -0.35 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Bone Biologics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.22,
with a Debt / Equity ratio of 0.
| Current Ratio | 10.22 |
| Quick Ratio | 10.22 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,056,210 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -45.33% in the
last 52 weeks. The beta is 1.17, so Bone Biologics's
price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | -45.33% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 56.47 |
| Average Volume (20 Days) | 161,334 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.22M |
| Net Income | -4.11M |
| EBITDA | -4.11M |
| EBIT | -4.11M |
| Earnings Per Share (EPS) | -4.83 |
Full Income StatementBalance Sheet
The company has 3.33M in cash and 0 in
debt, giving a net cash position of 3.33M.
| Cash & Cash Equivalents | 3.33M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -85.02M |
| Total Assets | 3.16M |
| Working Capital | 2.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -4.12M
and capital expenditures 0, giving a free cash flow of -4.12M.
| Operating Cash Flow | -4.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.12M |
| FCF Per Share | -2.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
